Trichlormethiazide

The FDA-approved drug library was from Enzo Lifesciences (Farmingdale, NY); selected drug candidates, oltipraz, trichlormethiazide, gemcitabine as well as trichostatin A (TSA), were from Sigma Aldrich. All substances were dissolved in dimethylsulfoxide (DMSO) with a maximum volume ratio of 0.1% in cell culture medium. Human p53 and HSF1 expression vectors were obtained from Origene (Rockville, MA).

Compounds were obtained from the following sources: 2-chlorobenzenesulfonamide, althiazide, bendroflumethiazide, benzthiazide, chlorothiazide, clopamide, cyclothiazide, dichlorofenamide, hydroflumethiazide, indapamide, metalozone, polythiazide, trichlormethiazide and xipamide were obtained from Sigma-Aldrich; chlorthalidone, clorexolone, fenquizone, and quinethazone were obtained from SantaCruz Biotechnology; hydrochlorothiazide and furosemide were obtained from AlfaAesar. Compound stock solutions (10–50) mM were prepared in dimethylsulfoxide (DMSO) and stored in a dark box at +4°C. Marvin was used for drawing, displaying and characterizing chemical structures, substructures and reactions; Marvin 19.4.0, 2019, ChemAxon (http://www.chemaxon.com).